Pilgrim's Pride heads into its Q1 2026 results with analysts on the back foot and the stock near oversold territory after a sharp month-long selloff.
The analyst community has been steadily trimming targets heading into this print. Goldman Sachs lowered its target from $44 to $39 on April 9, while BMO Capital cut from $42 to $40 in late March — both maintaining neutral-to-hold ratings. The consensus mean sits near $43, roughly 38% above the current price of $31.15, which points to a wide gap between where the Street thinks fair value is and where the market is pricing the stock today. The RSI has fallen to 31, deep into oversold territory. The stock is down 15% over the past month and shed another 5% on Tuesday alone.
The bull case rests on a valuation that looks historically cheap. EV/EBITDA has compressed to around 5.4x — a meaningful de-rating over the past month — while the PE ratio has drifted to roughly 7.9x. EPS is estimated near $3.93, and the EV/EBIT factor score ranks in the 94th percentile against the broader universe. Bears, however, point to deteriorating earnings momentum: the 30-day and 90-day EPS momentum scores rank in the bottom fifth of the market, at the 16th and 20th percentiles respectively. Forward EPS growth is flat year-on-year, and the stock has failed to hold any rally through the broader market turbulence of April.
Short positioning tells a restrained story. Short interest is only 2.2% of the free float — low in absolute terms — but it jumped 18% in the past week alone, rising from around 4.3 million shares to 5.25 million. The borrow market remains loose. Cost to borrow is a negligible 0.46%, and availability is ample, meaning there is no squeeze pressure building in the lending market. The short score, at 55, is moderate and has edged higher across recent sessions. Options positioning is mildly defensive — the put/call ratio is running at 1.10, just above its 20-day average of 1.07, a half standard deviation above the norm rather than a sharp hedge.
JBS N.V., the Brazilian meat giant and parent company, holds 82% of shares outstanding, leaving a thin free float and concentrating investor base risk. Among institutional holders, Dimensional Fund Advisors added roughly 742,000 shares in Q1 and Balyasny Asset Management built a new position of over 750,000 shares through year-end 2025 — two data points suggesting some active managers are looking through the near-term weakness. The CFO's most recent trade, a $303,000 sale in February, was small and routine rather than a signal in either direction.
The Q1 print will test whether the sharp valuation discount is warranted by deteriorating fundamentals, or whether it represents an overshoot that the company's free cash flow and margin profile can credibly close.
See the live data behind this article on ORTEX.
Open PPC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
